We are live on ! Find out more
CV

Clarus Ventures Portfolio holdings

AUM $425M
1-Year Est. Return 26.13%
This Fund
S&P 500
This Quarter Est. Return
-14.56%
1 Year Est. Return
+26.13%
3 Year Est. Return
+70.29%
5 Year Est. Return
+162.11%
10 Year Est. Return
–
AUM
$174M
AUM Growth
-$53.5M
Cap. Flow
+$948K
Cap. Flow %
0.55%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$1.14M

Top Sells

Rank Stock Value
1
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$194K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NSTG
1
DELISTED
NanoString Technologies, Inc.
NSTG
$63.4M 36.43%
3,959,440
– –
OXFD
2
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$29.1M 16.72%
2,153,092
-14,285
-0.7% -$194K
SIEN
3
DELISTED
Sientra, Inc.
SIEN
$27.7M 15.94%
273,077
– –
ATXS
4
DELISTED
Astria Therapeutics
ATXS
$22.3M 12.81%
45,875
– –
VBIV
5
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$13.1M 7.55%
165,703
– –
EVFM
6
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$8.65M 4.97%
11,905
– –
TLOG
7
DELISTED
TetraLogic Pharmaceuticals Corporation
TLOG
$8.59M 4.94%
4,644,705
– –
AERI
8
DELISTED
Aerie Pharmaceuticals
AERI
$1.12M 0.64%
+63,017
New +$1.14M

Similar funds

LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
VIA
Vantage Investment Advisors State College, Pennsylvania $477M AUM 17.38% 1-Year Est. Return
SPC
Salient Private Client Houston, Texas $513M AUM 10.97% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
CG
Clinton Group New York $279M AUM 4.76% 1-Year Est. Return
AAM
Amerigo Asset Management George Town, Cayman Islands $254M AUM 115.73% 1-Year Est. Return
SE
Summit Equities Parsippany, New Jersey $601M AUM 9.74% 1-Year Est. Return
CA
Cynosure Advisors Salt Lake City, Utah $238M AUM 4% 1-Year Est. Return

Clarus Ventures's Q3 2015 Portfolio in Review

As of Q3 2015, Clarus Ventures held 8 positions worth $174M, down 24% from $227M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Clarus Ventures's Q3 2015 filing shows 1 new and 1 reduced positions. Its largest new stake was Aerie Pharmaceuticals: 63,017 shares worth $1.12M. The largest sale was Oxford Immunotec Global PLC Ordinary Shares, an estimated $194K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Clarus Ventures's largest Q3 2015 buy was Aerie Pharmaceuticals: 63,017 shares worth $1.12M.
  • Clarus Ventures's biggest Q3 2015 reduction was Oxford Immunotec Global PLC Ordinary Shares, cutting an estimated $194K.
  • Clarus Ventures's ten largest holdings make up 100% of its $174M portfolio in Q3 2015.
  • Clarus Ventures opened 1 new position and closed 0 in Q3 2015.
  • Clarus Ventures's portfolio value fell 24% quarter-over-quarter to $174M.

Based on Clarus Ventures's 13F filing for Q3 2015, filed 12 Nov 2015.